The structural formula is:, diflucan and oral contraceptives. After reconstitution with 24 mL of distilled water or Purified Water USPeach mL of reconstituted suspension diflucan and oral contraceptives 10 mg or 40 mg of fluconazole.
Specimens for fungal culture and other relevant laboratory studies serology, histopathology should be obtained prior diflucan and oral contraceptives therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. In general, a loading dose of twice the daily dose is recommended on the first day of therapy to result in plasma concentrations close to steady-state by the second day of therapy.
Treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.
Clinical evidence of oropharyngeal candidiasis generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.
For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia, optimal therapeutic dosage and duration of therapy have not been established. In open, noncomparative studies of small numbers of patients, doses of up to mg daily have been used. For the treatment of Candida urinary tract infections and peritonitis, daily doses of mg have been used in open, noncomparative studies diflucan and oral contraceptives small numbers of patients. The recommended dosage for treatment of acute cryptococcal meningitis is mg on the first day, followed by mg once daily.
The recommended duration of treatment for initial therapy of cryptococcal meningitis is weeks after the cerebrospinal fluid becomes culture negative. Patients who are anticipated to have severe granulocytopenia less than neutrophils per cu mm should start DIFLUCAN prophylaxis several days before the anticipated onset of neutropeniaand continue for 7 days after the neutrophil count rises above cells per cu mm.
The following dose equivalency scheme should generally provide equivalent exposure in pediatric and adult patients:. After the first two weeks, these children should be dosed once daily. Treatment should be administered for at least 2 weeks to decrease the likelihood of relapse. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms. Fluconazole is cleared primarily by renal excretion as unchanged drug, diflucan and oral contraceptives.
There is no need to adjust single dose therapy for vaginal candidiasis because of impaired renal function. After the loading dose, the daily dose according to indication should be based on the following table:. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.
Further adjustment may be needed depending upon clinical condition. When serum creatinine is the only measure of renal function available, the cancer treatment interferon and avastin formula based on sex, weight, and age of the patient should be used to estimate the creatinine clearance in adults:. Although the pharmacokinetics of fluconazole has not been studied in children with renal insufficiency, dosage reduction in children with renal insufficiency should parallel that recommended for adults.
The following formula may be used to estimate creatinine clearance in children:. Prepare a suspension at time of dispensing as follows: To reconstitute, add 24 mL of distilled water or Purified Water USP to fluconazole bottle and shake vigorously to suspend powder.
Each bottle will deliver 35 mL of suspension. The concentrations of the reconstituted suspensions are as follows:. Shake oral suspension well before using. Pink trapezoidal tablets containing 50,or mg of fluconazole are packaged in bottles or unit dose blisters.
The mg fluconazole tablets are pink and oval shaped, packaged in a single dose unit blister. Bottles of diflucan and oral contraceptives NDC Unit dose package of Fluconazole mg per bottle NDC Fluconazole mg per bottle. In some patients, particularly those et tubes and lidocaine serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain.
Most of the reported side effects were mild to moderate in severity. Rarely, angioedema and anaphylactic reaction have been reported in marketing experience. Treatment was discontinued in 1. The proportions of patients discontinuing therapy due to clinical adverse events were similar in the two groups 1. The spectrum of these hepatic reactions has ranged from mild transient elevations in transaminases to clinical hepatitischolestasis and fulminant hepatic failure, including fatalities.
Instances of fatal hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions predominantly AIDS or malignancy and often while taking multiple concomitant medications, diflucan and oral contraceptives.
Transient hepatic reactions, including hepatitis and jaundicehave occurred among patients with no other identifiable risk factors.
These elevations occurred in patients with severe underlying disease, predominantly AIDS or malignancies, most of whom were receiving multiple concomitant medications, including many known to be hepatotoxic. The incidence of abnormally elevated diflucan and oral contraceptives transaminases was greater in patients taking DIFLUCAN concomitantly with one or more of the following medications: In diflucan and oral contraceptives cases, anaphylaxis including angioedema, face edema and pruritus has been reported.
Body as a Whole: Astheniafatigue, fever, diflucan and oral contraceptives, malaise. QT prolongation, torsade de pointes. Leukopeniaincluding neutropenia and agranulocytosisthrombocytopenia. Hypercholesterolemiahypertriglyceridemia, hypokalemia.
Cholestasis, dry mouthhepatocellular damage, dyspepsia, vomiting. Insomnia, paresthesiasomnolencetremorvertigo. Acute generalized exanthematous- pustulosisdrug eruption, increased sweating, exfoliative skin disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis see WARNINGSalopecia.
The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults. Thirteen percent of children experienced treatment-related adverse events. Treatment was discontinued in 2. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase, diflucan and oral contraceptives.
Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists days after discontinuation of fluconazole treatment due to the long half-life of fluconazole.
These are described in greater detail below:. When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
In post-marketing experience, as with other azole antifungals, bleeding events bruising, epistaxisgastrointestinal bleeding, hematuriaand melena have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin, diflucan and oral contraceptives.
Dose adjustment of warfarin may be necessary. This combination may be used by reducing the dosage of cyclosporine depending on cyclosporine concentration, diflucan and oral contraceptives. Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval.
Another study at a mg and mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of mg per day or greater significantly increases plasma levels of terfenadine when taken cholesterol and cinnamon. The combined use of fluconazole at doses of mg or greater with terfenadine is contraindicated.
There have been reports of cardiac events, including torsade de pointes, in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. The combined use of fluconazole with cisapride is contraindicated.
Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of torsade de pointes.
Coadministration of fluconazole and astemizole is contraindicated. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. Avoid concomitant administration of voriconazole and fluconazole, diflucan and oral contraceptives. Monitoring for adverse events and toxicity related to voriconazole is recommended; especially, if voriconazole is started within 24 h after the last dose of fluconazole.
Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines, diflucan and oral contraceptives. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously.
Increased tacrolimus levels have been associated with nephrotoxicity. Dosage of orally administered tacrolimus should be decreased depending on tacrolimus concentration. Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If short-acting benzodiazepines, which are metabolized by the cytochrome P system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
Systemic exposure to tofacitinib is increased when tofacitinib is coadministered with fluconazole, a combined moderate CYP3A4 and potent CYP2C19 inhibitor. Reduce the dose of tofacitinib when given concomitantly with fluconazole i. Dosage adjustments of triazolam may be necessary. Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. Thus, diflucan and oral contraceptives, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of diflucan and oral contraceptives combined oral contraceptive.
Although not studied in vitro cirrhosis and diabetes in vivo, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of torsade de pointes. Coadministration of fluconazole diflucan and oral contraceptives pimozide is contraindicated, diflucan and oral contraceptives.
Although not studied in vitro or in vivo, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism.